Tevogen Inc. Warrant (TVGNW)
TVGNW trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price · October 14, 2026
$0.0787
+12.59% on the day
Market cap
$512K
Nano cap
Revenue
Warrant: not a share of the company
Net income
Warrant: not a share of the company
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026.
Profile
| Field | Value |
|---|---|
| Ticker | TVGNW on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | United States |
| IPO year | 2022 |
| SEC CIK | 0001860871 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | DE |
Financials
Warrant: not a share of the company.
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B3 | 2026-06-26 |
| Latest annual report | 10-K/A | 2026-04-30 |
| Latest quarterly / interim | 10-Q | 2026-08-14 |
| Latest current report | 8-K | 2026-09-30 |
| Latest proxy | DEF 14A | 2026-08-03 |
Source: SEC EDGAR submissions feed, 305 recent filings. All filings on EDGAR.
Other listings for this company
| Ticker | Name | Price |
|---|---|---|
| TVGN | Tevogen Inc. | $7.11 |
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| SCLXW | Scilex Holding Company Warrant | $0.0621 | -14.35% | $527K |
| CRIS | Curis Inc. | $0.6149 | -4.42% | $1.3M |
| SCNI | Scinai Immunotherapeutics Ltd. | $1.23 | +6.03% | $1.7M |
| HLSQ | Tessera Defense and Homeland Security Inc. | $0.2600 | -7.08% | $2.3M |
| SLXN | Silexion Therapeutics Corp | $0.1760 | -1.24% | $2.5M |
| VIVS | VivoSim Labs Inc. | $0.1742 | +0.12% | $2.9M |
| CLDI | Calidi Biotherapeutics Inc. | $0.8999 | -5.26% | $3.3M |
| PMCB | PharmaCyte Biotech Inc. | $0.3559 | -2.52% | $3.8M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier